Adverse effects ‐ important extrapyramidal adverse effects · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects ‐ Blurred vision No of patients with blurred vision · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: blurred vision Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness, and other central nervous system adverse effects · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: drowsiness, hypersomnia, lethargy, excessive… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: impaired cognition Assessed by: adverse effect questionnaire (presence or absence given numerical values) · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: impaired cognition Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Adverse effectsb (mood disturbance, irritability, behavioural change, constipation) Measured by: counts of number and type · children with dystonic cerebral palsy
Summary of findings: Trihexyphenidyl may leads to higher adverse effectsb (mood disturbance, irritability, behavioural… compared with placebo (low certainty).
1 finding from 1 review
RR 2.54 [1.38, 4.67]
16 participants
Low
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects (tooth staining/discoloration, oral soft-tissue signs, adverse symptoms such as nausea/vomiting, enamel etching) · Children and adolescents aged 16 years or less
1 finding from 1 review
Data on adverse effects (stain score, proportion of children with tooth staining, signs of sensitivity in oral soft tissue, adverse symptoms such as nausea/vomiting, etching of enamel) were reported in only a few…
Studies not reported
GRADE not reported
Adverse effects: extrapyramidal adverse effects Parkinsonism medium term (3‐12 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Serious adverse events Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment · patients with Raynaud's phenomenon
1 finding from 1 review
Adverse effects / specific side effects (oral allergic reactions, mucosal irritation, adverse symptoms such as nausea, gagging, vomiting) · Children and adolescents aged 16 years or less
1 finding from 1 review
Hypokalaemia · preterm infants (< 37 weeks GA) at risk of chronic lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of antibiotics · prolonged wet cough in children
Antibiotics showed no clear difference in children experiencing adverse effects of antibiotics (e.g.… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects after treatment initiation: injection site reactions, neutropenia, infections, demyelinating disease, heart failure, malignancy, and induction of autoimmunity. · children diagnosed with Kawasaki disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbation (adverse effects) caused by inactivated influenza vaccine, measured in the first 2 weeks following vaccination ‐ adults given inactivated influenza vaccine · people with asthma
1 finding from 1 review